Table 1

Patient demographic and clinical data

ID#Sex/AgeSiteTNMF/U (mo)StatusXrt*p53 overexpressionp53 mutationHPV E6/E7
1M/63OC10026NED++H193R0
2M/70L3004NED+0WT0
3M/48L1b0026NED++WT0
4M/62Hypo42126DOD+R273L0
5M/58OP32024DOD+0WT1
6M/68OP12029NED+0WT0
7F/58OP10016NED+Y220C1
8M/60OC12023DOD++C275Y0
9M/54nd0207NED+0WT1
10M/50L30016NED+0Q192stop1
11F/65OC40012NED+ndndnd
12M/61nd02019NED+0WT1
13M/62OC40026AD++Y220H, Q317L0
14M/56nd32029NED0ndnd
15M/55OP02024NED++WT0
  • Abbreviations: OC, oral cavity; OP, oropharynx; HP, hypopharynx; L, larynx; nd, not determined; TNM, tumor-node-metastasis; NED, no evidence of disease; AD, active disease; DOD, dead of disease.

  • * Received radiation therapy ending 3 months postoperatively.

  • HPV-16 E6/E7 copy number was determined by quantitative real-time PCR (as described in Materials and Methods), with a lower threshold defined as at least one copy of E6 and/or E7 DNA per cellular genomic DNA equivalents by β-globin amplification.